Indication and Important Safety Information | Full Prescribing Information
Site User Guide

Viewing the Web Site

We want you to have the best experience possible when you visit our web site. Following are some guidelines (not requirements) you may want to follow for optimum viewing.

  • View our site with the latest Internet browsers: Netscape 7.x and Microsoft Internet Explorer 6.x.
  • Ensure that both Java and JavaScript are turned on. Note: latest versions of Internet browsers come with Java and JavaScript already enabled.
  • Set the resolution on your monitor to at least 800x600 to ensure you can view the full width of our web site in your browser window. Also set your monitor to view our site with at least 256 colors.

Printing Documents from the Web Site

PDF Documents:
There are a number of documents on our web site that are saved as Adobe Acrobat pdf documents so that you can download and view them with all their formatting and graphics intact. All you need to view these documents is the FREE Adobe Acrobat Reader. It is quick to download and will come in handy on a number of other web sites you visit as well.

Plug-ins

To enhance your visits to our web site, we utilize the following plug-ins which you can download FREE of charge.

  • Adobe Acrobat formats printed material for viewing on your computer monitor and allows you to print documents.
  • Flash is a plug-in from Macromedia that lets you experience content on the web by means of animation and sound.

Indication and Important Safety Information

Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.

A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).

For Full Prescribing Information, click here.